June 27, 2012
CHESTER, N.J.--(BUSINESS WIRE)--Sordoni Construction Company was selected as the construction manager for the Hemispherx Biopharma, Inc. facility enhancement project at their manufacturing site in New Brunswick, NJ. These improvements will enable Hemispherx to provide a high volume, more cost effective manufacturing process for Alferon N Injection® and Alferon® LDO. Alferon N Injection® is Hemispherx’s injectable formulation of natural interferon which is approved by the FDA for the treatment of certain categories of genital warts. Alferon® LDO is an experimental therapeutic being developed for multiple clinical indications including prevention, prophylaxis and treatment of influenza.
Sordoni will oversee and manage this multi-million dollar renovation of the existing manufacturing suite to a more efficient, less labor intensive up-graded process. The project includes full engineering studies, capital improvements, system upgrades and introduction of building management systems to enhance production. The main building is approximately 43,000 square feet and includes process piping, vessels, a bioreactor, class 100 hoods and a cold room. New utilities, including WFI, clean steam, process chiller and an emergency generator will also be added. In order to make the space for the new process suite, an existing mezzanine level will be demolished.
Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen® and Alferon® LDO) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. The planning, completion, results or submission of clinical trials do not imply that any study product will ever be approved commercially for the studied or other treatment indications.